Flu Vaccine Market Outlook 2024: United States Opportunity and Demand Analysis, Market Forecast 2017-2024
SKU ID :DPI-11200067 | Published Date: 21-Aug-2017 | No. of pages: 120Description
TOC
1. Executive Summary 2. Market Overview: United States Flu Vaccine Market (2010 - 2024) 3. United States Number of Persons Vaccinated with Flu Vaccine (2010 - 2024) 3.1 Number of Children Vaccinated 3.2 Number of Adults Vaccinated 4. Key Drivers and Inhibitors of the United States Flu Vaccine Market 4.1 Market Drivers 4.2 Market Inhibitors 5. United States Flu Vaccine Production, Price, Consumption, Supply, Distribution, Demand and Specification 5.1 Flu Vaccine Price Trends 5.1.1 Pediatric Flu Vaccine Price Trends 5.1.2 Adult Flu Vaccine Price Trends 5.2 United States Flu Vaccine Production, Supply, and Allocation (By Companies) 5.3 United States Flu Vaccine Distribution & Demand 5.4 Flu Vaccine Effectiveness 5.5 Managing Flu with Rapid Diagnostic Testing 5.6 Distribution Method of Flu Vaccination 6. United States Flu Vaccine Market – Reimbursement & Regulatory System 6.1 Reimbursement System 6.2 Regulation System 7. Market Dynamics – Mergers, Acquisitions, Key Agreements & Collaborations 7.1 Merger & Acquisitions 7.2 Collaboration Deal 7.3 Licensing, Exclusive & Distribution Agreement Deal 7.3.1 Licensing Agreement 7.3.2 Exclusive Agreement 7.3.3 Distribution Agreement 8. Flu Vaccine – Promising Vaccine in Clinical Development 8.1 Quadrivalent Seasonal Influenza VLP Vaccine 8.2 VN – 100 8.3 Seasonal Influenza VLP Vaccine 8.4 M–001 9. Flu Vaccine – Clinical Trial Insights by Phase, Company & Country 9.1 Year 2017 9.2 Year 2016 10. Key Companies Analysis 10.1 Sanofi Pasteur 10.1.1 Business Overview 10.1.2 Flu Vaccine Outlook 10.1.2.1 Fluzone High–Dose Vaccine 10.1.2.2 Fluzone Quadrivalent Vaccine 10.1.2.3 Intradermal (ID) Trivalent Flu Vaccine 10.1.2.4 Vaxigrip Vaccine 10.1.3 Flu Vaccine Sales Analysis & Forecast (2011 - 2024) 10.1.4 Flu Vaccine – Latest Development and Trends 10.2 GlaxoSmithKline (GSK) 10.2.1 Business Overview 10.2.2 Flu Vaccine Outlook 10.2.2.1 Fluarix Quadrivalent 10.2.2.2 Flulaval Quadrivalent 10.2.3 Flu Vaccine Sales Analysis & Forecast (2011 - 2024) 10.2.4 Flu Vaccine – Latest Development & Trends 10.3 Seqirus (CSL Limited) 10.3.1 Business Overview 10.3.2 Flu Vaccine Outlook 10.3.2.1 Flucelvax Quadrivalent 10.3.2.2 Afluria Quadrivalent 10.3.2.3 Agrippal 10.3.2.4 Fluad 10.3.2.5 Fluvirin 10.3.2.6 Fluvax 10.3.3 Flu Vaccine – Latest Development & Trends |
Tables & Figures
Table 5–2: United States – Pediatric Flu Vaccine Price, 2017 – 2018 Table 5–3: United States – Adult Flu Vaccine Price, 2017 – 2018 Table 5–4: United States – Flu Vaccine Production, Supply, and Allocation Table 5–5: Total Percentage of Flu Vaccines Released by Week,2016 – 2017 Table 5–6: Total Percentage of Flu Vaccines Released by Week,2015 – 2016 Table 5–7: Total Percentage of Flu Vaccines Released by Week,2014 – 2015 Table 5–8: Adjusted Vaccine Effectiveness Estimates for Flu Seasons, 2005 – 2016 Table 5–9: Influenza Virus Testing Methods Table 5–10: Distribution of Flu Vaccination Table 6–1: United States – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization Table 7–1: Flu Vaccine Market – Merger & Acquisitions (Million US$),2003 – 2017 Table 7–2: Flu Vaccine Market – Collaborations Deal,2007 – 2017 Table 7–3: Flu Vaccine Market – Licensing Agreement,2007 – 2016 Table 7–4: Flu Vaccine Market – Exclusive Agreement,2009 – 2016 Table 7–5: Flu Vaccine Market – Distribution Agreement,2005 – 2016
|
Companies
Seqirus, Sanofi Pasteur, GlaxoSmithKline(GSK) |
- PRICE
-
$1150$1700Buy Now